File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aldose reductase in diabetic microvascular complications

TitleAldose reductase in diabetic microvascular complications
Authors
KeywordsAldose reductase
Diabetic complications
Microvascular
Polyol pathway
Issue Date2005
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdt/index.htm
Citation
Current Drug Targets, 2005, v. 6 n. 4, p. 475-486 How to Cite?
AbstractMost long-term diabetic patients develop microvascular diseases such as retinopathy, nephropathy and neuropathy. Although tight control of blood glucose greatly reduces the incidence of these complications, a significant fraction of diabetic patients with good glycemic control still develop these diseases. Therefore, it is imperative to understand the underlying mechanisms of these diseases such that effective treatment or preventive methods can be developed to augment euglycemic control. In animal studies, there is strong evidence that aldose reductase, the first and rate-limiting enzyme of the polyol pathway that converts glucose to fructose, plays a key role in the pathogenesis of microvascular complications. However, clinical trials of the aldose reductase inhibitors were disappointing and several pharmaceutical companies had abandoned the development of this line of drugs. In this review, the potential pathogenic mechanisms of the polyol pathway are presented, the evidence for the involvement of the polyol pathway in diabetic complications summarized, and the reasons for the unimpressive results of the clinical trials of the aldose inhibitors discussed. It appears that renewed efforts to develop aldose reductase inhibitors for the treatment and prevention of diabetic complications are warranted. © 2005 Bentham Science Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/87980
ISSN
2015 Impact Factor: 3.029
2015 SCImago Journal Rankings: 1.211
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChung, SSMen_HK
dc.contributor.authorChung, SKen_HK
dc.date.accessioned2010-09-06T09:37:03Z-
dc.date.available2010-09-06T09:37:03Z-
dc.date.issued2005en_HK
dc.identifier.citationCurrent Drug Targets, 2005, v. 6 n. 4, p. 475-486en_HK
dc.identifier.issn1389-4501en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87980-
dc.description.abstractMost long-term diabetic patients develop microvascular diseases such as retinopathy, nephropathy and neuropathy. Although tight control of blood glucose greatly reduces the incidence of these complications, a significant fraction of diabetic patients with good glycemic control still develop these diseases. Therefore, it is imperative to understand the underlying mechanisms of these diseases such that effective treatment or preventive methods can be developed to augment euglycemic control. In animal studies, there is strong evidence that aldose reductase, the first and rate-limiting enzyme of the polyol pathway that converts glucose to fructose, plays a key role in the pathogenesis of microvascular complications. However, clinical trials of the aldose reductase inhibitors were disappointing and several pharmaceutical companies had abandoned the development of this line of drugs. In this review, the potential pathogenic mechanisms of the polyol pathway are presented, the evidence for the involvement of the polyol pathway in diabetic complications summarized, and the reasons for the unimpressive results of the clinical trials of the aldose inhibitors discussed. It appears that renewed efforts to develop aldose reductase inhibitors for the treatment and prevention of diabetic complications are warranted. © 2005 Bentham Science Publishers Ltd.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdt/index.htmen_HK
dc.relation.ispartofCurrent Drug Targetsen_HK
dc.subjectAldose reductaseen_HK
dc.subjectDiabetic complicationsen_HK
dc.subjectMicrovascularen_HK
dc.subjectPolyol pathwayen_HK
dc.subject.meshAldehyde Reductase - antagonists & inhibitors - physiologyen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshDiabetic Angiopathies - enzymology - etiologyen_HK
dc.subject.meshDiabetic Retinopathy - enzymology - etiologyen_HK
dc.subject.meshEnzyme Inhibitors - therapeutic useen_HK
dc.subject.meshExtracellular Matrix Proteins - metabolismen_HK
dc.subject.meshGlycosylationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshOsmotic Pressureen_HK
dc.subject.meshOxidative Stressen_HK
dc.subject.meshPolymers - metabolismen_HK
dc.subject.meshProtein Kinase C - physiologyen_HK
dc.titleAldose reductase in diabetic microvascular complicationsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1389-4501&volume=6&spage=475&epage=486&date=2005&atitle=Aldose+reductase+in+diabetic+microvascular+complicationsen_HK
dc.identifier.emailChung, SSM: smchung@hkucc.hku.hken_HK
dc.identifier.emailChung, SK: skchung@hkucc.hku.hken_HK
dc.identifier.authorityChung, SSM=rp00376en_HK
dc.identifier.authorityChung, SK=rp00381en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2174/1389450054021891en_HK
dc.identifier.pmid16026266-
dc.identifier.scopuseid_2-s2.0-21544463410en_HK
dc.identifier.hkuros106095en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-21544463410&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue4en_HK
dc.identifier.spage475en_HK
dc.identifier.epage486en_HK
dc.identifier.isiWOS:000230096000012-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridChung, SSM=14120761600en_HK
dc.identifier.scopusauthoridChung, SK=7404292976en_HK
dc.identifier.citeulike213544-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats